What happened
Windward Bio Group AG, a Swiss clinical-stage biotech, priced its IPO at $17 and finished its first session at $28.50. The company raised about $225 million when you combine the public listing with a private placement.
As part of the deal, Sanofi SA agreed to purchase $50 million of stock and pre-funded warrants. Jefferies Financial Group Inc., Toronto-Dominion Bank, Piper Sandler Cos., and UBS Group AG led the offering. On Nasdaq's Global Market, the stock lists under the ticker WWB.
Company background and investor roster
Founded in 2024, Windward is developing drugs for asthma, COPD (chronic obstructive pulmonary disease), and the skin condition atopic dermatitis. The plan for the proceeds is to push forward programs licensed from Sichuan Kelun-Biotech Biopharmaceutical Co., Harbour BioMed, and Qyuns Therapeutics Co.
Post deal, Novo Holdings A/S is expected to own nearly 11%, OrbiMed Private Investments about 10%, and CEO Luca Santarelli around 8%. The investor list also includes SR One, Omega Funds, RTW Investments, and Blue Owl Capital.
Savvy investors gain an edge by learning to use smarter tools thoughtfully. We're hosting our first ever investor livestream on 11/17 to show you how to use ChatGPT and Claude to invest like a pro, hosted by Briefs Finance CEO Jaspreet Singh. Save your seat.
Financial snapshot and what it means for your portfolio
Windward recorded $48.3 million in losses in 2025, compared with $1.2 million in losses for the stretch from its July incorporation through the end of 2024. With a first-day close that pegs the market value near $1.7 billion, the company now has public capital to advance its licensed pipeline, which is the lens to use when sizing WWB in a biotech allocation.
Staying disciplined and adopting new tools can quietly improve investment outcomes over time. On 11/17, our CEO Jaspreet Singh goes live for our first ever investor livestream on how to use ChatGPT and Claude to invest like a pro. Register to join him.
